TLR4 Is a Novel Determinant of the Response to Paclitaxel in Breast Cancer

Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-12-1019
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Trop-2 Is a Determinant of Breast Cancer Survival

PLoS ONE
Multidisciplinary
2014English

Paclitaxel in Breast Cancer

Oncologist
Cancer ResearchMedicineOncology
1998English

Enriched Variations in TEKT4 and Breast Cancer Resistance to Paclitaxel

Nature Communications
AstronomyGeneticsMolecular BiologyBiochemistryChemistryPhysics
2014English

The 4e-Bp1/eIF4E Ratio Is a Determinant for Rapamycin Response in Esophageal Cancer Cells

Journal of Thoracic and Cardiovascular Surgery
Respiratory MedicinePulmonaryCardiovascular MedicineSurgeryCardiology
2015English

Dramatic Response to Carboplatin, Paclitaxel, and Radiation in a Patient With Malignant Myoepithelioma of the Breast

Oncologist
Cancer ResearchMedicineOncology
2016English

Aurora Kinase a Stabilizes FOXM1 to Enhance Paclitaxel Resistance in Triple‐negative Breast Cancer

Journal of Cellular and Molecular Medicine
Molecular MedicineCell Biology
2019English

Anti-Her2 CD4+ T-Helper Type 1 Response Is a Novel Immune Correlate to Pathologic Response Following Neoadjuvant Therapy in HER2-positive Breast Cancer

Breast Cancer Research
Cancer ResearchOncology
2015English

Oral Paclitaxel in the Treatment of Metastatic Breast Cancer (MBC) Patients.

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2019English

Paclitaxel-Induced Apoptosis Is Blocked by Camptothecin in Human Breast and Pancreatic Cancer Cells

Oncology Reports
MedicineCancer ResearchOncology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy